Skye Bioscience Inc Dossier
Qualitative Analysis
Business overview
Skye Bioscience, Inc. (Nasdaq: SKYE) is a clinical-stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors (GPCRs) to treat metabolic health disorders, obesity, and overweight. The company's lead therapeutic candidate is nimacimab, a peripherally-restricted, negative allosteric modulating monoclonal antibody that targets the cannabinoid receptor 1 (CB1). By blocking peripheral CB1 receptors, nimacimab aims to directly improve metabolic processes, reduce fat storage, and increase energy expenditure without crossing the blood-brain barrier, thereby avoiding the neuropsychiatric side effects historically associated with small-molecule CB1 inhibitors. Skye previously discontinued its ophthalmic program (SBI-100 Ophthalmic Emulsion) to focus resources entirely on its metabolic and obesity pipeline.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
An expansion study designed to evaluate higher doses of nimacimab (400 mg and 600 mg IV, equivalent to ~700 mg and ~1000 mg subcutaneous doses respectively) once weekly versus matched placebo over a 16-week treatment period followed by 12 weeks of follow-up [1.1.5].
Expected impact: To generate higher-exposure human safety and pharmacokinetic data to inform optimal dose selection for the planned Phase 2b clinical study.
Preparatory activities to transition nimacimab into a Phase 2b-ready development program, including aligning with regulators on trial design, endpoints, and patient populations.
Expected impact: Enables the initiation of a larger Phase 2b study evaluating nimacimab as a complementary add-on approach for GLP-1-experienced patients.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Bird Rock Bio, Inc. provided Skye with nimacimab, a Phase 2-ready negative allosteric modulating antibody targeting CB1, which became Skye's primary clinical-stage asset.
Financial impact: The transaction was paid solely in shares of Skye's common stock (968,973,005 shares valued at approximately $20.0 million based on a 60-trading-day VWAP).
Strategic Partnerships
Skye licensed Halozyme's ENHANZE® drug delivery technology to develop and commercialize a subcutaneous formulation of nimacimab, enabling higher subcutaneous doses through larger injection volumes [1.3.2].
Terms: Skye will make milestone payments tied to development and commercialization events, and Halozyme is entitled to mid-single-digit royalties on net sales of nimacimab developed with ENHANZE® for at least 10 years.
To develop a novel, higher-concentration formulation of nimacimab using Arecor's proprietary Arestat™ formulation technology platform, aiming to facilitate less frequent dosing and improved treatment adherence.
Terms: Collaborative development agreement; specific financial milestones and royalty terms were not publicly disclosed.
To provide strategic guidance and written feedback on the nimacimab target product profile (TPP) and Phase 2b trial architecture.
Terms: Advisory consulting engagement; does not constitute a commitment regarding any future transaction, therapeutic interest, or exclusivity.